Indaptus Therapeutics Financial Results
Indaptus Therapeutics reported its Q3 2026 financial results, highlighting a cash and short-term investment position of approximately $30.6 million following a $24 million private placement. The company is shifting its strategic focus toward neurotechnology and neural-network-based devices for sleep-related conditions while significantly reducing R&D expenses by 82% year-over-year.
“Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.”
Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board
“We are particularly excited about the opportunity to explore the potential of an innovative neurotechnology- and neural-network-based device for certain sleep-related conditions. We believe this area represents an intriguing opportunity to investigate novel approaches to addressing unmet needs in sleep-related health. Through early-stage research and preclinical evaluation, we hope to further assess its scientific potential and explore a possible development pathway toward a future FDA submission.”
Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board